Astrazeneca (AZN)

[ADVERT]

Company name:	Astrazeneca Plc
Company Description:	A group engaged in R&D; manufacture & marketing of prescription pharmaceuticals & biological products for healthcare areas such as cardiovascular; neuroscience; oncology; respiratory & inflammation
EPIC:	AZN	Trading Currency:	GBX
Market Sector:	FE10	ISIN:	GB0009895292
Market Segment:	SET1	Share Type:	DE
WWW Address:	http://www.astrazeneca.com/	Description:	ORD SHS $0.25
Industry Sector:	PHARMACEUTICALS & BIOTECHNOLOGY

Price	Price Change [%]	Bid	Offer	Open	High	Low	Volume
8,347.00	63.0 [0.76]	8,347.00	8,348.00	8,386.00	8,404.00	8,306.00	429,160
Market Cap. [m]	Shares In Issue [m]	Beta	EPS	DPS	PE Ratio	Yield	52-Wks-Range
129,304.72	1,549.12	-1.99	184.74	204.80	45.18	2.45	9,523.00 - 6,736.00

Astrazeneca Key Figures

(at previous day's close)
Market Cap.	129,304.72	m
Shares In Issue	1,549.12	m
Prev. Close	8,284.00
PE Ratio	45.18
Dividend Yield	2.45	%
EPS - basic	184.74	p
Dividend PS	204.80	p
Dividend Cover	-
Cash Flow PS	226.59	p
Return On Equity (ROE)	20.46	%
Operating Margin	14.71	%
PEG Factor	0.33
EPS Growth Rate	136.89	%
Dividends PS Growth Rate	-	%
Net Debt	31,640.46	m
Gross Gearing	76.56	%
Quick Assets	14,171.98	m
Net Working Capital	2,262.28	m
Intangibles / Fixed Assets	77.22	%
Turnover PS	1,256.73	p
Pre-Tax Profit PS	184.89	p
Retained Profit PS	-17.75	p
Cash PS	369.79	p
Net Cash PS	-589.01	p
Net Tangible Asset Value PS *	-842.13	p
Net Asset Value PS	738.35	p
Spread	1.00 (0.01%)
* Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies.

Astrazeneca Balance Sheet

Share Price Performance

Sample Period ^†	High	Low
1 week	8,431.00	8,091.00
4 weeks	9,458.00	8,091.00
12 weeks	9,523.00	8,029.00
1 year	9,523.00	6,736.00

Share Price Chart (5 years)

Astrazeneca Historic Returns

Period ^†	Open	Change	%	Open Avg.	Avg. Daily Vol [m]	Total Vol [m]	VWAP
1 week	8,306.00	41.00	0.49	8,091.00	1.96		8,251.69
4 weeks	9,425.00	-1,078.00	-11.44	8,091.00	2.36		8,487.75
12 weeks	8,159.00	188.00	2.30	8,029.00	2.06		8,700.12
26 weeks	7,964.00	383.00	4.81	7,931.00	2.44		8,534.68
1 year	8,167.00	180.00	2.20	6,736.00	2.58		7,980.64
3 years	5,938.00	2,409.00	40.57	5,312.00	2.37		7,484.67
5 years	4,149.50	4,197.50	101.16	4,134.50	2.36		6,522.33
† periods calculated are whole weeks rather than calendar months

Astrazeneca Key Management Ratios

Astrazeneca Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio	122.44
PE Ratio	45.18
Tobin's Q Ratio	2.02
Tobin's Q Ratio (excl. intangibles)	4.21
Dividend Yield	2.45	%
Market-to-Book Ratio	11.32
Price-to-Pre-Tax Profit PS	45.14
Price-to-Retained Profit PS	-470.18
Price-to-Cash Flow PS	36.84
Price-to-Sales PS	6.64
Price-to-Net Tangible Asset Value PS	-9.92
Price-to-Cash PS	22.57
Net Working Capital PS	146.04
Price Pct to Working Capital PS	57.16	%
Earnings Yield	2.21	%
Average PE	35.20
Years in average	5
PE to PE average	128.37	%

Astrazeneca Financial Ratios

(Leverage Ratios)
Debt Ratio	66.31	%
Debt-to-Equity Ratio	1.97
Debt-to-Equity Ratio (excl. Intgbl)	-1.73
Debt-to-Equity Market Value	0.17
Net Gearing	64.83	%
Net Gearing (excl. Intangibles)	130.02	%
Gross Gearing	76.56	%
Gross Gearing (excl. Intangibles)	153.56	%
Gearing Under 1 Year	30.43	%
Gearing Under 1 Year (excl. Intgbl)	61.04	%
Assets/Equity	4.27
Cash/Equity	50.08
(Liquidity Ratios)
Net Working Capital to Total Assets	4.64	%
Current Ratio	1.15
Quick Ratio (Acid Test)	0.95
Liquidity Ratio	0.39
Cash & Equiv/Current Assets	33.47	%
(Solvency Ratios)
Enterprise Value	146,103.96	m
CFO/Sales	0.18
CFO/Attributable Profit	1.50
CFO/Assets	0.07
CFO/Debt	0.09
Total Debt/Equity Market Value	0.29
Total Debt/Sales	1.92
Total Debt/Pre-Tax Profit	13.05
Total Debt	37,368.94	m
Total Debt/Net Current Assets	16.52	%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth	12.80	%
5 yr Compound Earnings Growth	-	%
10 yr Compound Earnings Growth	-	%
Earn drops > 5% in 10yrs	9

Beta (60-Mnth)	Beta (36-Mnth)
-1.9875	-0.5367

Astrazeneca Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)	8.44	%
Return On Assets (ROA)	3.65	%
Net Profit Margin	12.01	%
Assets Turnover	0.30
Return On Equity (ROE)	20.46	%
Return On Investment (ROI)	5.21	%
Dividend Payout Ratio	114.75	%
Plowback Ratio	-14.75	%
Growth from Plowback Ratio	-2.40	%
Net Income Of Revenues	-1.41	%
(Asset Utilisation Multiples)
Shareholders Equity Turnover	1.35
Fixed Assets Turnover	0.45
Current Assets Turnover	0.94
Net Working Capital Turnover
Inventory Turnover	5.40
(Other Operating Ratios)
Total Assets-to-Sales	3.29
Debtors-to-Sales	54.06	%
Debt Collection Period	197.31	Days

Astrazeneca Dividends

Announcement Date	Type	Curr.	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
29 Jul 2021	Interim	USX	90.00	31/12/2020	31/12/2021	12/08/2021	13/08/2021	13/09/2021	-
16 Feb 2021	Interim	USX	190.00	31/12/2019	31/12/2020	25/02/2021	26/02/2021	29/03/2021	280.00
30 Jul 2020	Interim	USX	90.00	31/12/2019	31/12/2020	13/08/2020	14/08/2020	14/09/2020	-
14 Feb 2020	Interim	USX	190.00	31/12/2018	31/12/2019	27/02/2020	28/02/2020	30/03/2020	280.00
25 Jul 2019	Interim	USX	90.00	31/12/2018	31/12/2019	08/08/2019	09/08/2019	09/09/2019	-
14 Feb 2019	Final	USX	190.00	31/12/2017	31/12/2018	28/02/2019	01/03/2019	27/03/2019	280.00
26 Jul 2018	Interim	USX	90.00	31/12/2017	31/12/2018	09/08/2018	10/08/2018	10/09/2018	-
02 Feb 2018	Final	USX	190.00	31/12/2016	31/12/2017	15/02/2018	16/02/2018	19/03/2018	280.00
27 Jul 2017	Interim	USX	90.00	31/12/2016	31/12/2017	10/08/2017	11/08/2017	11/09/2017	-
02 Feb 2017	Final	USX	190.00	31/12/2015	31/12/2016	16/02/2017	17/02/2017	20/03/2017	280.00
28 Jul 2016	Interim	USX	90.00	31/12/2015	31/12/2016	11/08/2016	12/08/2016	12/09/2016	-
04 Feb 2016	Final	USX	190.00	31/12/2014	31/12/2015	18/02/2016	19/02/2016	21/03/2016	280.00
30 Jul 2015	Interim	USX	90.00	31/12/2014	31/12/2015	13/08/2015	14/08/2015	14/09/2015	-
05 Feb 2015	Final	USX	190.00	31/12/2013	31/12/2014	19/02/2015	20/02/2015	23/03/2015	280.00
31 Jul 2014	Interim	USX	90.00	31/12/2013	31/12/2014	13/08/2014	15/08/2014	15/09/2014	-
06 Feb 2014	Final	USX	190.00	31/12/2012	31/12/2013	19/02/2014	21/02/2014	24/03/2014	280.00
01 Aug 2013	Interim	USX	90.00	31/12/2012	31/12/2013	14/08/2013	16/08/2013	16/09/2013	-
31 Jan 2013	Final	USX	190.00	31/12/2011	31/12/2012	13/02/2013	15/02/2013	18/03/2013	280.00
26 Jul 2012	Interim	USX	90.00	31/12/2011	31/12/2012	08/08/2012	10/08/2012	10/09/2012	-
02 Feb 2012	Final	USX	195.00	31/12/2010	31/12/2011	15/02/2012	17/02/2012	19/03/2012	280.00
28 Jul 2011	Interim	USX	85.00	31/12/2010	31/12/2011	03/08/2011	05/08/2011	12/09/2011	-
27 Jan 2011	Final	USX	185.00	31/12/2009	31/12/2010	02/02/2011	04/02/2011	14/03/2011	255.00
29 Jul 2010	Interim	USX	70.00	31/12/2009	31/12/2010	02/08/2010	04/08/2010	13/09/2010	-
28 Jan 2010	Final	USX	171.00	31/12/2008	31/12/2009	03/02/2010	05/02/2010	15/03/2010	230.00
30 Jul 2009	Interim	USX	59.00	30/12/2008	30/06/2009	05/08/2009	07/08/2009	14/09/2009	-
29 Jan 2009	Final	USX	150.00	31/12/2007	31/12/2008	04/02/2009	06/02/2009	16/03/2009	205.00
31 Jul 2008	Interim	USX	55.00	30/12/2007	30/06/2008	08/08/2008	06/08/2008	15/09/2008	-
31 Jan 2008	Final	USX	135.00	31/12/2006	31/12/2007	06/02/2008	08/02/2008	17/03/2008	187.00
26 Jul 2007	Interim	USX	52.00	30/06/2006	30/06/2007	08/08/2007	10/08/2007	17/09/2007	-
01 Feb 2007	Final	USX	123.00	31/12/2005	31/12/2006	07/02/2007	09/02/2007	19/03/2007	172.00
27 Jul 2006	Interim	USX	49.00	30/12/2005	30/06/2006	09/08/2006	11/08/2006	18/09/2006	-
01 Feb 2006	Final	USX	92.00	31/12/2004	31/12/2005	08/02/2006	10/02/2006	20/03/2006	130.00
29 Jul 2005	Interim	USX	38.00	30/12/2004	30/06/2005	10/08/2005	12/08/2005	19/09/2005	-
27 Jan 2005	Final	USX	64.50	31/12/2003	31/12/2004	09/02/2005	11/02/2005	21/03/2005	94.00
22 Jul 2004	Interim	USX	29.50	30/12/2003	30/06/2004	11/08/2004	13/08/2004	20/09/2004	-
29 Jan 2004	Final	USX	54.00	31/12/2002	31/12/2003	18/02/2004	20/02/2004	06/04/2004	79.50
24 Jul 2003	Interim	USX	25.50	30/12/2002	30/06/2003	20/08/2003	22/08/2003	06/10/2003	-
30 Jan 2003	Final	USX	47.00	31/12/2001	31/12/2002	19/02/2003	21/02/2003	07/04/2003	70.00
25 Jul 2002	Interim	USX	23.00	30/12/2001	30/06/2002	21/08/2002	23/08/2002	07/10/2002	-
31 Jan 2002	Final	USX	47.00	31/12/2000	31/12/2001	20/02/2002	22/02/2002	08/04/2002	70.00
26 Jul 2001	Interim	USX	23.00	30/12/2000	30/06/2001	22/08/2001	24/08/2001	05/10/2001	-
08 Feb 2001	Final	USX	47.00	31/12/1999	31/12/2000	21/02/2001	23/02/2001	09/04/2001	70.00
01 Aug 2000	Interim	USX	23.00	30/12/1999	30/06/2000	04/09/2000	08/09/2000	23/10/2000	-
24 Feb 2000	Final	USX	47.00	31/12/1998	31/12/1999	06/03/2000	10/03/2000	17/04/2000	70.00
03 Aug 1999	Interim	USX	23.00	30/12/1998	30/06/1999	06/09/1999	10/09/1999	25/10/1999	-

Astrazeneca Fundamentals

	31 Dec 2017 (USD)		31 Dec 2018 (USD)		31 Dec 2019 (USD)		31 Dec 2020 (USD)
turnover	22,465.00	100.00%	22,090.00	100.00%	24,384.00	100.00%	26,617.00	100.00%	m
pre tax profit	2,227.00	9.91%	1,993.00	9.02%	1,548.00	6.35%	3,916.00	14.71%	m
attributable profit	3,001.00	13.36%	2,155.00	9.76%	1,335.00	5.47%	3,196.00	12.01%	m
retained profit	-518.00	-2.31%	-1,329.00	-6.02%	-2,257.00	-9.26%	-376.00	-1.41%	m
eps - basic	237.00		170.00		103.00		244.00
eps - diluted	237.00		170.00		103.00		244.00
dividends per share	280.00		280.00		280.00		280.00

Astrazeneca Balance Sheet

	31 Dec 2017 (USD)		31 Dec 2018 (USD)		31 Dec 2019 (USD)		31 Dec 2020 (USD)


	31 Dec 2017 (USD)		31 Dec 2018 (USD)		31 Dec 2019 (USD)		31 Dec 2020 (USD)
ASSETS
fixed assets	7,615.00	12.02%	7,421.00	12.24%	7,688.00	12.53%	8,251.00	12.36%	m
intangibles	38,013.00	60.00%	33,666.00	55.51%	33,148.00	54.01%	33,458.00	50.14%	m
fixed investments	2,798.00	4.42%	2,186.00	3.60%	2,405.00	3.92%	1,620.00	2.43%	m
current assets - other	-	-%	-	-%	70.00	0.11%	-	-%	m
stocks	3,035.00	4.79%	2,890.00	4.76%	3,193.00	5.20%	4,024.00	6.03%	m
debtors	8,569.00	13.53%	9,657.00	15.92%	9,504.00	15.48%	11,544.00	17.30%	m
cash & securities	3,324.00	5.25%	4,831.00	7.97%	5,369.00	8.75%	7,832.00	11.74%	m

TOTAL	63,354.00	100%	60,651.00	100%	61,377.00	100%	66,729.00	100%	m

LIABILITIES
creditors - short	16,383.00	25.86%	16,292.00	26.86%	18,117.00	29.52%	20,307.00	30.43%	m
creditors - long	30,329.00	47.87%	30,315.00	49.98%	28,664.00	46.70%	30,784.00	46.13%	m
creditors - other	-	-%	-	-%	-	-%	-	-%	m
subordinated loans	-	-%	-	-%	-	-%	-	-%	m
insurance funds	-	-%	-	-%	-	-%	-	-%	m

TOTAL	46,712.00	73.73%	46,607.00	76.84%	46,781.00	76.22%	51,091.00	76.56%	m

EQUITY
ord cap, reserves	14,960.00	23.61%	12,468.00	20.56%	13,127.00	21.39%	15,622.00	23.41%	m
prefs, minorities	1,682.00	2.65%	1,576.00	2.60%	1,469.00	2.39%	16.00	0.02%	m

TOTAL	16,642.00	26.27%	14,044.00	23.16%	14,596.00	23.78%	15,638.00	23.44%	m

OTHER
NAV Basic	-		-		-		-
NAV Diluted	-		-		-		-

Astrazeneca Cash Flow Statement

	31 Dec 2017 (USD)	31 Dec 2018 (USD)	31 Dec 2019 (USD)	31 Dec 2020 (USD)
Operating CF	3,578.00	2,618.00	2,969.00	4,799.00	m
Pre-Financing CF	1,250.00	3,581.00	2,312.00	4,514.00	m
Retained CF	-1,686.00	1,537.00	547.00	2,311.00	m

Astrazeneca Brokers

Name	Activity	Type	Mnemonic	Code
Evolution Securities Limited	Market Maker(MME)	Broker/Dealer	EVO	EVBGGB21MMT
Nyenburgh Holding B.V.	Market Maker(MME)	Broker/Dealer	NYBB	NYENNL2B
Winterflood Securities Ltd	Market Maker(MME)	Broker/Dealer	WINS	WNTSGB2LBIC